The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today ...

Rebrain SAS's Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to ...

Gene and cell therapies (GCTs) can target the kidney to treat congenital, acute or chronic diseases affecting this organ.